Pentoxifylline for injection

1. Verapamil hydrochloride is a calcium ion antagonist. It exerts its pharmacological effects by regulating the influx of calcium ions on the cell membranes of myocardial conduction cells, myocardial contractile cells, and arterial smooth muscle cells, but does not change the serum calcium concentration. 2. Verapamil hydrochloride dilates the main coronary arteries and arterioles in normal and ischemic parts of the heart, antagonizes spontaneous or ergonovine-induced coronary artery spasm, increases the delivery of myocardial oxygen to patients with coronary artery spasm, relieves and prevents coronary artery spasm; Verapamil reduces total peripheral resistance and reduces myocardial oxygen consumption. It can be used to treat variant angina and unstable angina. 3. Verapamil reduces calcium ion influx, prolongs the effective refractory period of the atrioventricular node, slows conduction, and can reduce the ventricular rate of patients with chronic atrial fibrillation and atrial flutter; it reduces the frequency of paroxysmal supraventricular tachycardia. Usually, verapamil does not affect the normal sinus rate, but it can cause sinus arrest or sinoatrial block in patients with sick sinus syndrome; verapamil does not change the action potential or intraventricular conduction time of the normal atrium, but it reduces the amplitude, speed and conduction speed of the depolarization of the inhibited atrial fibers, which may shorten the forward effective refractory period of the additional bypass channel, accelerate the ventricular rate of patients with atrioventricular bypass combined with atrial flutter or atrial fibrillation, and even induce ventricular fibrillation. 4. Verapamil produces a blood pressure-lowering effect by reducing the vascular resistance of the systemic circulation, and generally does not cause postural hypotension or reflex tachycardia. 5. Verapamil reduces afterload, inhibits myocardial contraction, and can improve left ventricular diastolic function. In isometric or dynamic myocardial exercise, verapamil does not change the cardiac contractile function of patients with normal ventricular function. In patients with organic heart disease, the negative inotropic effect of verapamil can be offset by the effect of reducing afterload, and the cardiac index does not decrease. However, patients with severe left ventricular dysfunction (e.g., pulmonary wedge pressure greater than 20 mmHg or ejection fraction less than 30%), or patients taking beta-blockers or other myocardial depressant drugs, may experience worsening of cardiac function. 6. Animal experiments suggest that the local anesthetic effect of verapamil is 1.6 times that of procaine equimolar. The effect and dosage in humans are still unclear. Carcinogenicity, mutagenicity and reproductive toxicity Verapamil is not carcinogenic. The Ames test confirmed that verapamil is not mutagenic. Long-term use of verapamil ge;30mg/(kgd) by Beagle dogs resulted in lens-shaped and/or suture-shaped changes, and ge;62.5mg/(kgd) caused cataracts with obvious symptoms. There have been no reports of cataract formation in humans due to taking verapamil. No impairment of fertility was observed in female mice. The effect on human fertility is still unclear.

3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6-dione

This product is white or off-white loose lumps.

1. Cerebral blood circulation disorders such as transient cerebral ischemic attack, sequelae of stroke, brain dysfunction caused by cerebral ischemia; 2. Peripheral blood circulation disorders such as thromboembolic vasculitis, abdominal arterial blood circulation disorders, intermittent claudication or rest pain; 3. Inner ear circulation disorders such as sudden deafness, senile tinnitus and deafness. 4. Eye blood circulation disorders.

Intravenous drip. The patient should be in a supine position during use. The initial dose is 100 mg of pentoxifylline, which is infused within 2-3 hours, and the maximum drip rate should not exceed 100 mg/hour. Depending on the patient's tolerance, the dose can be increased by 50 mg each time, but the dose should not exceed 200 mg each time, 1-2 times a day. The maximum dose should not exceed 400 mg/24 hours.

1 Common adverse reactions include: nausea, dizziness, headache, anorexia, abdominal distension, vomiting, etc., with an incidence rate of more than 5%. 2 Less common adverse reactions include cardiovascular system: decreased blood pressure, irregular breathing, edema; nervous system: anxiety, depression, convulsions; digestive system: anorexia, constipation, dry mouth, thirst; skin: angioedema, rash, shiny nails; as well as blurred vision, conjunctivitis, enlarged central blind spot, decreased taste, increased saliva, leukopenia, muscle soreness, weight change, etc. 3 Occasional adverse reactions include angina pectoris, arrhythmia; jaundice, hepatitis, abnormal liver function, decreased blood fibrinogen, aplastic anemia, etc.

This product is contraindicated for patients who are allergic to pentoxifylline, patients with cerebral hemorrhage, extensive retinal hemorrhage, acute myocardial infarction, pregnant women, patients with severe coronary artery and cerebral vascular sclerosis accompanied by hypertension, and patients with severe arrhythmia.

Precautions during pregnancy and lactation: Contraindicated for pregnant women

1. Cytotoxic drugs such as cyclophosphamide, vincristine, procarbazine, prednisone, vinblastine, doxorubicin, and cisplatin reduce the absorption of verapamil. 2. Phenobarbital, hydantoin, vitamin D, sulfinpyrazone, and ramifluan reduce the plasma concentration of verapamil by increasing liver metabolism. 3. Cimetidine may increase the bioavailability of verapamil. 4. Verapamil inhibits the elimination of ethanol, leading to an increase in the concentration of ethanol in the blood, which may prolong the toxic effects of alcohol. 5. A few cases reported that the bleeding time of verapamil combined with aspirin was prolonged compared with aspirin alone. 6. Combined use with beta-receptor blockers can enhance the inhibitory effect on atrioventricular conduction. 7. Long-term use of verapamil increases the blood concentration of digoxin by 50-75%. Verapamil significantly affects the pharmacokinetics of digoxin in patients with cirrhosis, reducing the total clearance and extrarenal clearance of digoxin by 27% and 29%, respectively. Therefore, when taking verapamil, the dose of digoxin and digitalis must be reduced. 8. When used in combination with antihypertensive drugs such as vasodilators, angiotensin-converting enzyme inhibitors, and diuretics, the antihypertensive effect is superimposed, and patients receiving combined antihypertensive therapy should be appropriately monitored. 9. Combination with amiodarone may increase cardiac toxicity. 10. Patients with subaortic stenosis due to hypertrophic cardiomyopathy should avoid combined medication. 11. When verapamil is used in combination with flecainide, negative inotropic effects can be superimposed and atrioventricular conduction can be prolonged. 12. Verapamil can increase the blood concentration of carbamazepine, cyclosporine, doxorubicin, and theophylline. 13. There are reports that verapamil increases patients' sensitivity to lithium (neurotoxicity). 14. Animal experiments suggest that when inhaled anesthetics are used simultaneously with verapamil, the doses of the two drugs need to be carefully adjusted to avoid excessive cardiac inhibition. 15. Avoid using verapamil and disopyramide simultaneously.

Keep away from light and sealed. Valid for 18 months.

0.1g

Jilin Huinan Changlong BLO-CHEMICAL Pharmaceutcal Co., Ltd.

• Founded in:

  1996-08-19

• Address:

  No. 31, Beishan Street, Chaoyang Town, Huinan County, Jilin Province

• Tax NO.:

  91220501243809189J

• Registered Funds:

  56.02 million yuan

• Website:

  Log in to view

• Email:

  Log in to view